Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cardiol Therapeutics (CRDL) Shares Outstanding (2021 - 2025)

Cardiol Therapeutics filings provide 2 years of Shares Outstanding readings, the most recent being $47.2 million for Q4 2022.

  • On a quarterly basis, Shares Outstanding fell 3.96% to $47.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $47.2 million, a 3.96% decrease, with the full-year FY2022 number at $47.2 million, down 3.96% from a year prior.
  • Shares Outstanding hit $47.2 million in Q4 2022 for Cardiol Therapeutics, down from $49.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $49.1 million in Q4 2021 to a low of $47.2 million in Q4 2022.